To print: Select File and then Print from your browser's menu
---------------------------------------------------------------------------------------
Title: Health Canada Approves Ceftobiprole Medocaril for Treatment of Complicated Skin Structure Infections
URL: http://www.pslgroup.com/dg/22A776.htm
Doctor's Guide
September 2, 2008

NEW YORK -- September 2, 2008 -- Health Canada has approved ceftobiprole medocaril IV (Zeftera) for the treatment of complicated skin and skin structure infections (cSSSI), including non-limb-threatening diabetic foot infections without concomitant osteomyelitis.

Ceftobiprole medocaril IV is also effective against methicillin-resistant Staphylococcus aureus (MRSA).

The approval was based on results of 2 phase 3, double-blind, randomised, multicentre, global trials involving 817 patients with cSSSI.

The first study demonstrated the efficacy of ceftobiprole medocaril compared with vancomycin alone in patients with suspected or confirmed gram-positive cSSSI, and a second study demonstrated the effectiveness of ceftobiprole medocaril when compared with vancomycin plus ceftazidime.

The second phase 3 trial included patients with non-limb-threatening diabetic foot infections. Pathogens identified at baseline in this subpopulation included methicillin-sensitive S. aureus (38%), MRSA (13%), Enterobacter cloacae (9%), and Proteus mirabilis (7%). The results demonstrated the effectiveness of ceftobiprole medocaril when compared with vancomycin plus ceftazidime.

In both studies, ceftobiprole medocaril was well tolerated. The most common treatment-emergent adverse reactions were nausea (9%), taste disturbance (6%), diarrhoea (5%), and vomiting (5%).

SOURCE: Environics Communications Press Release

---------------------------------------------------------------------------------------------
Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.
---------------------------------------------------------------------------------------------
This news story was printed from *Doctor's Guide to the Internet*
located at http://www.docguide.com
---------------------------------------------------------------------------------------

Return to News Story Page

This site is maintained by webmaster@pslgroup.com
Please contact us with any comments, problems or bugs.
All contents Copyright (c) 1998 P\S\L Consulting Group Inc.
All rights reserved.